ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

piflufolastat

Also written as “Piflufolastat F 18 Intravenous Solution [PYLARIFY]”, “piflufolastat (18F)” and “piflufolastat F 18”.

Its studies are mostly in Prostatic Neoplasms · Carcinoma, Renal Cell, led by 2 companies.

Drug pagePiflufolastat: every studyAll 30 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Oct 3, 20235 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Lantheus40 open or runningphase 4since Oct 3, 2023Nov 22, 2016none ahead
Braccoits history only10 open or runningphase 4since Sep 17, 2024Sep 17, 2024none ahead

Also a collaborator on its studies: Aixial Group.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Lantheus only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Nov 22, 2016First study: phase 3 study in Prostatic NeoplasmsFirst studyNCT02981368 · 385 enrolled · United States, Canada
  2. Nov 9, 2018Phase 3 study in Prostatic NeoplasmsNCT03739684 · 208 enrolled · United States, Canada
  3. Jan 25, 2022Named piflufolastatINNProposed as its International Nonproprietary Name in WHO's List 126
  4. Oct 3, 2023Phase 4 study in Prostatic NeoplasmsNCT06074510 · 279 enrolled · United States
  5. May 30, 2025Phase 3 study in Carcinoma, Renal CellNCT07084909 · United States

TargetBeta

FOLH1 →read by rule
“A urea-based radiotracer composed of the prostate specific membrane antigen (PSMA) targeting agent DCFPyL and ”NCIt, by rule

Other programs on FOLH1

ProgramCompanyFurthest phaseStudies
flotufolastat F 18ruleBraccophase 47
abefolastat tesaroxetan CU-64ruleclarity-pharmaceuticals-ltdphase 35
gallium 68 PSMA-11ruleNovartisphase 34
Lutetium Lu 177 Ludotadipeprulefuturechemphase 33
Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401Johnson & Johnsonphase 32
Lutetium Lu 177 NYM032ruleNorroy Biosciencephase 32
actinium AC-225 vipivotide tetraxetanNovartisphase 32
HRS-4357Jiangsu HengRui Medicinephase 32
zadavotide guraxetanAstraZenecaphase 24
AB-001rulefrontier-biotechnologies-incphase 23
olsutamigruleRegeneron Pharmaceuticalsphase 22
SHR-4394Jiangsu HengRui Medicinephase 22

Studies

All 4 Lantheus leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07084909Carcinoma, Renal Cell · United States3WithdrawnSep 20270
NCT06074510Prostatic Neoplasms · United States4CompletedAug 28, 2026279
NCT03739684Prostatic Neoplasms · United States, Canada3CompletedAug 29, 2019208
NCT02981368Prostatic Neoplasms · United States, Canada3CompletedJul 2018385

How it is read

Names in the registry

  • “Piflufolastat F 18 Intravenous Solution [PYLARIFY]”, 1 entry
  • “piflufolastat (18F)”, 1 entry
  • “piflufolastat F 18”, 1 entry
  • “18F-DCFPyL Injection”, 1 entry
  • “18F-DCFPyL”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.